147 related articles for article (PubMed ID: 10562769)
21. Grepafloxacin in respiratory tract infections: are we ready to accept a quinolone for empirical treatment?
Norrby SR
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():99-101. PubMed ID: 9484879
[No Abstract] [Full Text] [Related]
22. In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
Isenberg HD; Alperstein P; France K
Diagn Microbiol Infect Dis; 1998 Oct; 32(2):115-8. PubMed ID: 9823535
[TBL] [Abstract][Full Text] [Related]
23. Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin.
Drugeon HB; Juvin ME; Bryskier A
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():55-9. PubMed ID: 10404339
[TBL] [Abstract][Full Text] [Related]
24. Latest industry information on the safety profile of levofloxacin in Japan.
Yagawa K
Chemotherapy; 2001; 47 Suppl 3():38-43; discussion 44-8. PubMed ID: 11549788
[TBL] [Abstract][Full Text] [Related]
25. [Levofloxacin for prevalent infections in primary care medicine].
Redondo Sánchez J
Enferm Infecc Microbiol Clin; 1999; 17 Suppl 1():29-33. PubMed ID: 10563108
[No Abstract] [Full Text] [Related]
26. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
[TBL] [Abstract][Full Text] [Related]
27. Prulifloxacin versus levofloxacin in the treatment of respiratory and urinary tract infections: a multicentre, double-blind, randomized controlled clinical trial.
Chen Y; Yang H; Lu G; Wu X; Huang W; Wu Y; Lv X; Wu G; Zhang G; Li Q; Sun Y
Chemotherapy; 2012; 58(3):249-56. PubMed ID: 22890091
[TBL] [Abstract][Full Text] [Related]
28. In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas.
Bébéar CM; Renaudin H; Schaeverbeke T; Leblanc F; Bébéar C
J Antimicrob Chemother; 1999 May; 43(5):711-4. PubMed ID: 10382895
[TBL] [Abstract][Full Text] [Related]
29. Levofloxacin: a therapeutic review.
Wimer SM; Schoonover L; Garrison MW
Clin Ther; 1998; 20(6):1049-70. PubMed ID: 9916602
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
Malmborg AS; Ahlén S
Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
[TBL] [Abstract][Full Text] [Related]
31. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
[TBL] [Abstract][Full Text] [Related]
32. [Grepafloxacin (Vaxar)--innovative antibiotic for therapy of respiratory tract infections. Symposium: "Grepafloxacin--a new quinolone designed for respiratory tract infection. Lausanne/Switzerland, 25 May 1997].
Pneumologie; 1997 Sep; 51(9 Suppl):1-4. PubMed ID: 9417540
[No Abstract] [Full Text] [Related]
33. Quinolone activity against anaerobes.
Appelbaum PC
Drugs; 1999; 58 Suppl 2():60-4. PubMed ID: 10553708
[TBL] [Abstract][Full Text] [Related]
34. Antimicrobial activity of gemifloxacin (SB-265805), a newer fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae, including fluoroquinolone-resistant isolates.
Tanaka M; Tunoe H; Mochida O; Kanayama A; Saika T; Kobayashi I; Naito S
Diagn Microbiol Infect Dis; 2000 Oct; 38(2):109-13. PubMed ID: 11035242
[TBL] [Abstract][Full Text] [Related]
35. [Levofloxacin (Tavanic) in the treatment of corneal ulcers].
Maĭchuk IuF
Antibiot Khimioter; 2003; 48(6):16-9. PubMed ID: 14558414
[TBL] [Abstract][Full Text] [Related]
36. Detection of fluoroquinolones in urinary specimens from patients undergoing anti-tuberculous therapy.
Chan CY; Tsang DS; Chan TL; Yew WW; Cheung SW; Cheng AF
Chemotherapy; 1998; 44(1):7-11. PubMed ID: 9444402
[TBL] [Abstract][Full Text] [Related]
37. Moxifloxacin: new preparation. A me-too with more cardiac risks.
Prescrire Int; 2002 Dec; 11(62):168-9. PubMed ID: 12469694
[TBL] [Abstract][Full Text] [Related]
38. Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'.
Fish DN
Expert Rev Anti Infect Ther; 2003 Oct; 1(3):371-87. PubMed ID: 15482135
[TBL] [Abstract][Full Text] [Related]
39. Grepafloxacin--focus on respiratory infections.
Geddes AM
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():1-4. PubMed ID: 9484866
[No Abstract] [Full Text] [Related]
40. Resistance to ciprofloxacin and the new fluoroquinolones.
Hawkey PM
J Chemother; 2000 Jan; 12 Suppl 1():12-4. PubMed ID: 11414380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
